-
WST-8 Glucose Uptake Assay Kit Guide
2026-09-28
The WST-8 Glucose Uptake Assay Kit is a non-radioactive glucose uptake assay that converts 2-deoxyglucose metabolism into a 450 nm colorimetric signal. Its stated 10–500 μM linear range supports quantitative cellular glucose metabolism assay workflows when cell number, treatment conditions, and assay controls are standardized.
-
GOB-38 in Elizabethkingia anophelis: Enzyme Profile
2026-09-28
The study characterizes GOB-38, a metallo-β-lactamase variant from Elizabethkingia anophelis, and reports activity across penicillins, cephalosporins, and carbapenems. Its recombinant-enzyme and co-culture work connects substrate specificity with possible resistance implications, while leaving the scale and mechanism of resistance transfer to be established.
-
Mycophenolic acid in immune metabolism assays
2026-09-27
Use Mycophenolic acid to test how disrupting nucleotide biosynthesis changes stimulated immune-cell responses in a whole-blood assay. This practical guide covers compound handling, controlled dose finding, cytokine readouts, and troubleshooting while separating workflow recommendations from published findings.
-
Ceruletide Workflows for Pancreatic Fibrosis Research
2026-09-26
Use Ceruletide to build controlled caerulein-based pancreatic injury models and investigate how injury connects to fibrosis, autophagy, and gastrointestinal function. This guide pairs practical peptide handling with readouts that help distinguish disease-model effects from direct receptor or cell-signaling mechanisms.
-
Doxorubicin and the Persister-State Opportunity
2026-09-25
Doxorubicin is a powerful DNA-damage benchmark—but surviving cells may reveal biology beyond initial cytotoxicity. Learn how to connect its established mechanism with persister-state lipidomic research while keeping the evidence and experimental claims in perspective.
-
RBMS1 Loss Rewires PD-L1 Stability in TNBC
2026-09-25
A 2022 study links the RNA-binding protein RBMS1 to PD-L1 stability in triple-negative breast cancer through regulation of B4GALT1 mRNA and PD-L1 glycosylation. The findings nominate RBMS1 as an immunoregulatory target and support testing its loss alongside cellular immunotherapies, while leaving clinical efficacy and broader transferability unresolved.
-
ICI 118,551 Hydrochloride: Evidence and Limits
2026-09-24
ICI 118,551 hydrochloride is a β2-adrenoceptor antagonist research compound, but the cited stroke study investigated esculetin, not ICI 118,551. The study supports an esculetin–CKLF1–neutrophil mechanism in its experimental models; it does not establish a role for ICI 118,551 in stroke treatment.
-
Azilsartan Medoxomil: AT1 Blockade in Hypertension
2026-09-24
This 2017 MiniReview connects azilsartan medoxomil’s sustained AT1-receptor binding with clinical evidence of blood-pressure reduction, while noting that improved cardiovascular outcomes have not been established. Its literature-search approach and discussion of pharmacokinetics offer useful context for designing receptor and hypertension studies, but the findings should be interpreted as a narrative synthesis rather than a new trial or meta-analysis.
-
Hydrocortisone Butyrate for Reliable Cell Assays
2026-09-23
A practical guide to using Hydrocortisone butyrate (Hydrocortisone 17-butyrate), SKU N2898, in cell-based inflammation and viability workflows. It covers concentration selection, handling, interpretation of delivery-study data, and evidence-based product evaluation without assuming undocumented assay performance.
-
DIDS: Workflows for Chloride and Tumor Studies
2026-09-23
DIDS is a practical perturbation tool for connecting chloride transport, membrane signaling, vascular physiology, and cell-death biology. This guide translates its reported channel activity into controlled dose-response workflows and shows how the reference metastasis study can be tested without mistaking a broad pharmacological effect for target selectivity.
-
Regorafenib, RRM2, and Melanoma Progression
2026-09-22
A 2024 iScience study identifies RRM2 reduction as a functional component of Regorafenib activity in melanoma, linking the drug to ERK/E2F3 signaling, apoptosis, and suppression of invasive behavior. Its combined use of phenotypic assays, RNA sequencing, perturbation experiments, and in vivo validation provides a mechanistic framework for cancer biology research while leaving important translational questions unresolved.
-
How Near-Death Tumor Cells Seed Metastasis
2026-09-22
Conod, Silvano, and Ruiz i Altaba show that tumor cells surviving an impending-death experience can enter stable prometastatic states rather than simply recover from injury. Their study defines PAMEs, links them to ER stress, reprogramming, stemness, and a cytokine storm, and identifies PAME-induced migratory cells as a paracrine mechanism that may organize metastatic tumor ecosystems.
-
Bifendate Inhibits Autophagy at Multiple Steps
2026-09-21
The reference study identifies Bifendate (DDB) as a multi-step autophagy inhibitor rather than a compound that simply changes autophagy marker abundance. Using cell-based lysosomal and lipid-accumulation models, the authors show that DDB interferes with autophagosome–lysosome fusion, lysosomal acidification, and autophagic lysosome reformation while reducing oleic acid-induced lipid droplets.
-
VE-821: Selective ATR Kinase Inhibitor Guide
2026-09-21
VE-821 is an ATP-competitive ATR kinase inhibitor for DNA damage response inhibitor studies, radiosensitization assays, and chemotherapy sensitization research. Vendor-reported biochemical potency and cellular findings support its use as a controlled in vitro tool, while the available evidence does not establish clinical or antiviral efficacy.
-
Berberrubine chloride: Research Workflows
2026-09-20
Berberrubine chloride supports mechanism-led studies spanning colorectal cancer, NSCLC chemosensitization, urate transport, and enzyme-mediated drug interaction research. This workflow-focused guide covers DMSO preparation, cell and enzyme assay design, reference-study translation, and troubleshooting for more reproducible results.